Register for our free email digests:
Value-Added Medicines
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Alvogen Strikes Deals For Pfenex’ Teriparatide
Alvogen has signed marketing deals with local firms in Canada, Israel and South Korea for the teriparatide drug it has licensed from Pfenex. In the US, Pfenex has just completed a human factors study it feels should support a therapeutic equivalence rating for its Forteo rival.
Value Added Medicines Hold Promise Despite Challenges
An IQVIA report dives into how technology can facilitate a digital future for value added medicines, while discussing the market size, opportunities, scope of growth and challenges for this emerging sector in healthcare.
Early Dialogue And Patient Involvement Can Unlock Value
Recognizing the benefits of value added medicines in European hospital settings can help patients and healthcare professionals, a KPMG report commissioned by Medicines for Europe suggests.
Stoller Sets Agenda As Medicines For Europe’s President
Christoph Stoller, Teva’s general manager for Germany and Austria, has just been announced as president of European off-patent industry association Medicines for Europe with a two-year mandate. In an exclusive interview, he sets out the organization’s immediate priorities.
Shortlist Revealed For Industry Awards
Shortlists for each of the 14 categories in the Global Generics & Biosimilars Awards 2019 have been announced, after our panel of expert judges considered almost 100 entries.
US Study Lends Support To Polypill Proposals
Fixed-dose polypills containing commonly available generic cardiovascular agents could cut risks in low-income populations within the US, a randomized clinical trial suggests.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.